Diabetes & Metabolic Medicines · LP-061
Metformin Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-061Diabetes & Metabolic Medicines
- Generic identity
- MetforminTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-061
- Generic identity
- Metformin
- Presentation
- Tablet
- Catalogue strength
- 500 mg; 850 mg; 1000 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: metformin.
- Dosage form: tablet.
- Proposed strengths: 500 mg, 850 mg and 1000 mg.
- General proposed pack: blister 10 × 10 tablets.
Layer 02 · Unresolved product-specific fields
- Release characteristics for all strengths.
- Score/divisibility, coating and formulation details.
- Approved indications, dosing/titration, renal-function requirements and warnings.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 500 mg | Tablet | — | General blister pack | Immediate/modified release is not identified. |
| B | 850 mg | Tablet | — | General blister pack | Immediate/modified release is not identified. |
| C | 1000 mg | Tablet | — | General blister pack | Immediate/modified release is not identified. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Metformin is a glucose-lowering medicine used in selected type 2 diabetes management plans. It reduces hepatic glucose production and has different effects from medicines that directly stimulate insulin secretion. Immediate-release and modified-release products may have different instructions. This profile supplies general ingredient education, not Luang Pharma approved labeling, and does not confirm the release characteristics or equivalence of the proposed tablets.
Clinical context and therapeutic role
A clinician evaluates glycaemic goals, renal function, gastrointestinal tolerability and other health conditions when selecting metformin. The wider plan may include additional medicines and cardiovascular risk management. Acute illness, dehydration, surgery or contrast-related procedures can require a review of ongoing treatment. Long-term use can affect vitamin B12 status, especially when anemia or neuropathic symptoms develop. A catalogue page cannot replace an individualized monitoring and sick-day plan.
Selected safety context
Gastrointestinal upset is common. Rare lactic acidosis is a serious concern, particularly with significant renal impairment, severe acute illness, hypoxia or other predisposing circumstances. Unusual profound weakness, breathing difficulty, persistent vomiting or marked deterioration requires urgent assessment. Alcohol intake and interacting medicines should be discussed. Metformin alone is less likely to cause hypoglycaemia than insulin-releasing medicines, but combined treatment can change that risk. Renal function and possible vitamin B12 deficiency warrant professional review.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A diabetes-care professional should confirm the formulation, glycaemic objective, renal function and hypoglycaemia risk. The person should have an individualized monitoring and illness plan; this educational page does not supply dose-selection or conversion instructions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product formulation/specification identifying release characteristics.
Approved label including renal and administration information.
Registration/market-status evidence.
Manufacturing-site/release documentation as applicable.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B06 checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: MetforminArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-061.
Professional enquiries
Request product-specific evidence for LP-061.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.